Comparison between patients included in or excluded from clinical trials for small cell lung cancer (SCLC) - Lung Cancerdoi:10.1016/0169-5002(94)94166-1D.ArpinandC.LassetandF.ChauvinandJ.F.Lung Cancer
IMforte is a Phase 3 clinical trial evaluating lurbinectedin in combination with the PD-L1 inhibitor atezolizumab as a first-line maintenance treatment for patients with extensive-stage small cell lung cancer (ES-SCLC). The trial, conducted in collaboration with F. Hoffmann-La Roche Ltd (Roche...
DeLLphi Clinical Trials are available to patients with Small-Cell Lung Cancer (SCLC)Amgen Oncology is testing the investigational drug tarlatamab to see how safe and effective it is at treating patients who have small-cell lung cancer (SCLC)....
Clinical trials have also served to clarify the role of surgery in a disease that traditionally has been thought to be nonoperable. This review will focus on the results of clinical trials that have had an effect on the treatments of patients with limited and extensive-stage SCLC, with ...
Clinical trial information is sourced from ClinicalTrials.gov. The efficacy and safety of the agents and/or uses under investigation have not been established. There is no guarantee that the agents will receive health authority approval or become commercially available in any country for the uses ...
Patients with limited-stage SCLC treated during a similar time interval were also evaluated in the Surveillance, Epidemiology, and End Results (SEER) database. Trends were tested in the number of trials, in the number and gender of patients entered on trial, and in survival duration over time...
The hepatocellular carcinoma (HCC) space has been presented with a number of trials exploring immune-oncology (IO) therapies combined with VEGF antibodies, tyrosine kinase inhibitors (TKIs), and more over the past 5 years. Currently, more than 1 standard-of-care option exists in this space, in...
Comparison of lung cancer clinical trials treatment options and standard practice in Brazilian national health system over the last decade. e18678#Background:New cancer drugs for metastatic non-small cell (NSCLC) and small cell lung cancer (SCLC) have been approved worldwide in the past decade,...
Clinical trials categorize mTOR inhibitors for various cancer types, demonstrating their efficacy in suppressing CSC differentiation, intrinsic stem cell properties, and reducing metastasis. Despite promising results, caution is warranted in mTOR inhibition due to its involvement in normal cellular activities...
地塞米松也在第4天和第5天同时给药。主要终点是在开始化疗后的整个阶段(第1-8天)内完全缓解(无呕吐和无抢救治疗)的受试者比例。测定P物质和5-HT的基线血浆浓度以进行探索性分析。该研究已在ClinicalTrials.gov上注册,编号为NCT04536558...